European Biotech Gives Lower Returns At Exit

The Life Sci VC blog has provided an analysis of venture-backed biotech M&A figures for 2012.  It notes 3 main trends:

– median investor return multiples have risen from 2.5x in 2011 to 3.5x in 2012.

– European biotech exits have a far lower invested capital to return multiple. In 2012 it was 1.3x for Europe and 3.5x for the US.

– time from founding to trade sale has increased from 5 years in 2005 to 9 years in 2012.

Pondering on the lower returns for European exits, it’s not too surprising.  I know that in the UK at least, there is far less money in the system and that must lead to companies being bought out more cheaply. It’s more difficult to be optimistic about the future when financing is hard to get.  However I would also propose from personal experience that UK biotech is more insular than US biotech, at both the academic and research company levels, and that means it is less responsive and less influenced by commercial considerations.  I would imagine fewer UK companies know their market as well as US companies, to the extent for example where they would have analysed the likelihood of their product outcompeting existing products.  That means European companies are at risk of developing technologies which may be excellent, but which are going to make less money than technologies chosen and developed with an eye on the commercial considerations.


4 thoughts on “European Biotech Gives Lower Returns At Exit

    1. hollyipltd Post author

      Thank you for your comment. US biotech is not located in a particular place (so there isn’t a Silicon Valley equivalent). I think it’s just slightly ahead of us in the lifecycle of the industry. Biotech is filled with academics thinking in an academic way, rather than a commercial way, and the US is ahead in recognising that. I think the strength the US has is that it is capable of learning its commercial lessons quicker, particularly in areas where the free market is operating most effectively. In Europe we don’t treat business/commercial skills with the same respect, and so we are less appreciative of having to learn and hone these.

      1. wmistudymovie

        Yes, I’d say that there is this division in the UK and Europe between ‘academic’ (or almost anything else) and ‘commercial’ that doesn’t exist in the US to the same degree. That said, in areas away from biotech this may not be such a strength; as with so much else, it’s about finding that balance.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s